We here investigated the combination of different TKI and blinatumomab in BCR::ABL1+ and BCR::ABL1− B-ALL cell lines and primary samples regarding T cell proliferation, differentiation, cytokine release and killing of tumor cells. Here, ABL1 is linked to neoplasm.